scholarly journals De novo design of protein peptides to block association of the SARS-CoV-2 spike protein with human ACE2

Aging ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 11263-11276 ◽  
Author(s):  
Xiaoqiang Huang ◽  
Robin Pearce ◽  
Yang Zhang
Keyword(s):  
De Novo ◽  
De Novo Design ◽  
Spike Protein ◽  
Block Association

scholarly journals Computer-Aided Approaches to De Novo Design of drug candidates targeting the SARS-CoV-2 Spike protein bound to angiotensin converting enzyme 2 (ACE2)

2021 ◽  
Author(s):  
Konstantinos Kalamatianos
Keyword(s):  
De Novo ◽  
Md Simulations ◽  
De Novo Design ◽  
Design Tool ◽  
Spike Protein ◽  
De Novo Drug Design ◽  
Angiotensin Converting Enzyme 2 ◽  
Lipinski’S Rule ◽  
Drug Candidates ◽  
Computer Aided

In this study a computer-aided approach to de novo design of chemical entities with drug-like properties against the SARS-CoV-2 Spike protein bound to ACE2 is presented. A structure-based de novo drug design tool LIGANN was used to produce complementary ligand shapes to the SARS-CoV-2 Spike protein (6M0J). The obtained ligand structures - potential drug candidates – were optimized and virtually screened. Hit ligands were considered all that showed initial binding energy scores ≤ -9.0 kcal.mol-1 for the protein. These compounds were tested for drug-likeness (Lipinski’s rule and BOILED Permeation Predictive Model). All satisfying the criteria were re-optimized (geometry & frequencies) at the HF-3c33 level of theory and virtually screened against 6M0J. Molecular dynamics (MD) simulations were used to assess the structural stability of selected 6M0J/novel compound complexes. Synthetic pathways for selected compounds from commercially available starting materials are proposed.

scholarly journals Computer-Aided Approaches to De Novo Design of drug candidates targeting the SARS-CoV-2 Spike protein bound to angiotensin converting enzyme 2 (ACE2)

2021 ◽  
Author(s):  
Konstantinos Kalamatianos
Keyword(s):  
De Novo ◽  
Md Simulations ◽  
De Novo Design ◽  
Design Tool ◽  
Spike Protein ◽  
De Novo Drug Design ◽  
Angiotensin Converting Enzyme 2 ◽  
Lipinski’S Rule ◽  
Drug Candidates ◽  
Computer Aided

In this study a computer-aided approach to de novo design of chemical entities with drug-like properties against the SARS-CoV-2 Spike protein bound to ACE2 is presented. A structure-based de novo drug design tool LIGANN was used to produce complementary ligand shapes to the SARS-CoV-2 Spike protein (6M0J). The obtained ligand structures - potential drug candidates – were optimized and virtually screened. Hit ligands were considered all that showed initial binding energy scores ≤ -9.0 kcal.mol-1 for the protein. These compounds were tested for drug-likeness (Lipinski’s rule and BOILED Permeation Predictive Model). All satisfying the criteria were re-optimized (geometry & frequencies) at the HF-3c33 level of theory and virtually screened against 6M0J. Molecular dynamics (MD) simulations were used to assess the structural stability of selected 6M0J/novel compound complexes. Synthetic pathways for selected compounds from commercially available starting materials are proposed.

Towards the de novo design of DNA based catalytic sites using a combined NMR and in silico approach

2014 ◽  
Author(s):  
Dieter Buyst ◽  
V. Gheerardijn ◽  
J. Van Den Begin ◽  
A. Madder ◽  
J. C. Martins
Keyword(s):  
In Silico ◽  
De Novo ◽  
De Novo Design ◽  
Catalytic Sites

scholarly journals De Novo Design of Selective Quadruplex‐Duplex Junction Ligands and Structural Characterisation of their Binding Mode: Targeting the G4 Hot‐Spot

2020 ◽  
Author(s):  
Laura Díaz-Casado ◽  
Israel Serrano-Chacón ◽  
Laura Montalvillo-Jiménez ◽  
Francisco Corzana ◽  
Agatha Bastida ◽  
...  
Keyword(s):  
De Novo ◽  
Hot Spot ◽  
Binding Mode ◽  
De Novo Design ◽  
Structural Characterisation

scholarly journals De novo design of modular and tunable protein biosensors

Nature ◽  
2021 ◽  
Author(s):  
Alfredo Quijano-Rubio ◽  
Hsien-Wei Yeh ◽  
Jooyoung Park ◽  
Hansol Lee ◽  
Robert A. Langan ◽  
...  
Keyword(s):  
De Novo ◽  
De Novo Design

scholarly journals Front Cover: De Novo Design of Selective Quadruplex–Duplex Junction Ligands and Structural Characterisation of Their Binding Mode: Targeting the G4 Hot‐Spot (Chem. Eur. J. 20/2021)

2021 ◽  
Vol 27 (20) ◽  
pp. 6101-6101
Author(s):  
Laura Díaz‐Casado ◽  
Israel Serrano‐Chacón ◽  
Laura Montalvillo‐Jiménez ◽  
Francisco Corzana ◽  
Agatha Bastida ◽  
...  
Keyword(s):  
De Novo ◽  
Hot Spot ◽  
Binding Mode ◽  
De Novo Design ◽  
Front Cover ◽  
Structural Characterisation

scholarly journals Stereotypic neutralizing VH antibodies against SARS-CoV-2 spike protein receptor binding domain in COVID-19 patients and healthy individuals

2021 ◽  
pp. eabd6990
Author(s):  
Sang Il Kim ◽  
Jinsung Noh ◽  
Sujeong Kim ◽  
Younggeun Choi ◽  
Duck Kyun Yoo ◽  
...  
Keyword(s):  
B Cells ◽  
Receptor Binding ◽  
Neutralizing Antibodies ◽  
De Novo ◽  
Binding Domain ◽  
Host Cells ◽  
Spike Protein ◽  
Receptor Binding Domain ◽  
Healthy Individuals

Stereotypic antibody clonotypes exist in healthy individuals and may provide protective immunity against viral infections by neutralization. We observed that 13 out of 17 patients with COVID-19 had stereotypic variable heavy chain (VH) antibody clonotypes directed against the receptor-binding domain (RBD) of SARS-CoV-2 spike protein. These antibody clonotypes were comprised of immunoglobulin heavy variable (IGHV)3-53 or IGHV3-66 and immunoglobulin heavy joining (IGHJ)6 genes. These clonotypes included IgM, IgG3, IgG1, IgA1, IgG2, and IgA2 subtypes and had minimal somatic mutations, which suggested swift class switching after SARS-CoV-2 infection. The different immunoglobulin heavy variable chains were paired with diverse light chains resulting in binding to the RBD of SARS-CoV-2 spike protein. Human antibodies specific for the RBD can neutralize SARS-CoV-2 by inhibiting entry into host cells. We observed that one of these stereotypic neutralizing antibodies could inhibit viral replication in vitro using a clinical isolate of SARS-CoV-2. We also found that these VH clonotypes existed in six out of 10 healthy individuals, with IgM isotypes predominating. These findings suggest that stereotypic clonotypes can develop de novo from naïve B cells and not from memory B cells established from prior exposure to similar viruses. The expeditious and stereotypic expansion of these clonotypes may have occurred in patients infected with SARS-CoV-2 because they were already present.

Sign in / Sign up

Export Citation Format

Share Document